Published 07 February 2018
Chinese biotechnology company NetVation DL Medicine, which is focused on the discovery and development of novel drug candidates, has entered into a two-year research collaboration with Pfizer.
Under the terms of the agreement, DL Medicine will screen and collaborate with Pfizer in producing new chemical entities against pre-selected targets from multiple therapeutic areas.
As part of the collaboration, Pfizer has taken a financial stake in DL Medicine.
DL Medicine utilizes resources, funding and emerging technologies from the expanding biotechnology capabilities of the growing life sciences industry in China and employs novel approaches to identify and develop new drug candidates.
Research conducted under this collaboration will utilize HitGen’s DNA-encoded libraries to validate early targets, identify novel chemical matter, and conduct lead optimization. Compounds that meet specific requirements will be advanced further in the discovery process. Additional screening technology platforms will also be utilized.
DL Medicine CEO Wei Chen said: “We are delighted to announce this collaboration with Pfizer, and we look forward to working together to potentially discover new chemical entities for the treatment of diseases that negatively impact the health of patients worldwide.”
Pfizer external science & innovation executive director Yuan-Hua Ding said: “New target ideas and novel chemical matter are critical to our success in bringing new therapies to patients around the world.
“This collaboration represents our worldwide commitment to partnering with companies that are doing innovative scientific work to help enhance our portfolio across multiple disease areas.”
Source: Company Press Release